Equities Analysts Issue Forecasts for Immunovant Q2 Earnings

Key Points

• Leerink Partners has decreased its Q2 2026 earnings per share (EPS) estimate for Immunovant from ($0.66) to ($0.71), with a full-year EPS estimate of ($2.69).
• The company's recent quarterly earnings showed an EPS of ($0.60), surpassing the consensus estimate of ($0.69) by $0.09.
• Immunovant's stock is currently trading at $15.32, showing a significant drop from its 12-month high of $34.47.

Immunovant, Inc. (NASDAQ:IMVT - Free Report) - Investment analysts at Leerink Partnrs decreased their Q2 2026 EPS estimates for Immunovant in a research note issued to investors on Monday, August 11th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings per share of ($0.71) for the quarter, down from their previous estimate of ($0.66). The consensus estimate for Immunovant's current full-year earnings is ($2.69) per share. Leerink Partnrs also issued estimates for Immunovant's Q3 2026 earnings at ($0.72) EPS, Q4 2026 earnings at ($0.73) EPS, FY2026 earnings at ($2.87) EPS, FY2027 earnings at ($3.06) EPS, FY2028 earnings at ($2.48) EPS, FY2029 earnings at ($1.35) EPS and FY2030 earnings at $0.85 EPS.

Several other equities analysts have also issued reports on IMVT. Citigroup reiterated a "buy" rating on shares of Immunovant in a report on Monday, August 11th. JPMorgan Chase & Co. lowered their target price on shares of Immunovant from $40.00 to $37.00 and set an "overweight" rating for the company in a report on Tuesday, August 12th. The Goldman Sachs Group upgraded shares of Immunovant to a "hold" rating and set a $18.00 target price for the company in a report on Thursday, July 10th. Bank of America dropped their target price on shares of Immunovant from $33.00 to $30.00 and set a "buy" rating on the stock in a report on Tuesday, August 12th. Finally, UBS Group increased their price target on shares of Immunovant from $17.00 to $18.00 and gave the stock a "neutral" rating in a research report on Monday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $35.20.

Immunovant Stock Down 2.2%

Shares of IMVT stock traded down $0.34 during trading hours on Thursday, hitting $14.92. 369,445 shares of the company's stock traded hands, compared to its average volume of 1,460,126. The stock's fifty day simple moving average is $16.48 and its two-hundred day simple moving average is $16.82. Immunovant has a 12-month low of $12.72 and a 12-month high of $34.47. The stock has a market cap of $2.60 billion, a price-to-earnings ratio of -5.23 and a beta of 0.66.

Immunovant (NASDAQ:IMVT - Get Free Report) last released its earnings results on Monday, August 11th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.09. During the same quarter in the previous year, the business earned ($0.60) EPS.

Insiders Place Their Bets

In related news, CTO Jay S. Stout sold 2,805 shares of Immunovant stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $18.15, for a total transaction of $50,910.75. Following the completion of the transaction, the chief technology officer directly owned 204,919 shares of the company's stock, valued at approximately $3,719,279.85. The trade was a 1.35% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Michael Geffner sold 2,385 shares of Immunovant stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $18.15, for a total transaction of $43,287.75. Following the transaction, the insider directly owned 221,825 shares of the company's stock, valued at approximately $4,026,123.75. This represents a 1.06% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 7,869 shares of company stock valued at $140,384 over the last three months. Corporate insiders own 1.80% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Vanguard Group Inc. increased its stake in Immunovant by 3.9% during the 1st quarter. Vanguard Group Inc. now owns 6,936,859 shares of the company's stock valued at $118,551,000 after purchasing an additional 257,445 shares in the last quarter. Deep Track Capital LP boosted its holdings in Immunovant by 38.0% during the fourth quarter. Deep Track Capital LP now owns 6,000,000 shares of the company's stock worth $148,620,000 after buying an additional 1,652,536 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its holdings in Immunovant by 15.2% during the first quarter. T. Rowe Price Investment Management Inc. now owns 5,894,824 shares of the company's stock worth $100,743,000 after buying an additional 777,590 shares in the last quarter. Baker BROS. Advisors LP raised its position in Immunovant by 219.6% during the first quarter. Baker BROS. Advisors LP now owns 5,457,881 shares of the company's stock worth $93,275,000 after acquiring an additional 3,750,000 shares during the period. Finally, Alpine Global Management LLC raised its position in Immunovant by 21.7% during the first quarter. Alpine Global Management LLC now owns 2,626,692 shares of the company's stock worth $44,890,000 after acquiring an additional 467,788 shares during the period. Institutional investors own 47.08% of the company's stock.

Immunovant Company Profile

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.